Entresto Logo 2020.png
novartis_rm_logo_pos_rgb.png
H2H_Logos_RGB_Webinar.png
H2H_Heart_Hands.png

HFSN competency workshop

This promotional meeting is organised and funded by Novartis Pharmaceuticals UK Limited.

UK | March 2022 | 193547

Entresto (sacubitril/valsartan) is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.

(Ref: https://www.medicines.org.uk/emc/product/5074/smpc)

Adverse events should be reported. Reporting forms and information can be found at  www.mhra.gov.UK/yellowcard (UK).

Adverse events should also be reported to Novartis via  uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at  www.report.novartis.com

 

If you have a question about a product, please contact Medical Information on 01276 698370 or by email at  medinfo.uk@novartis.com

To learn about your data privacy rights and the use of your personal information, we invite you to read our General Privacy Notice for Business Partners.